Ali Ardakani is a technical and entrepreneurial corporate development & operations biotech executive with over 20 years of experience in managing life science projects and companies. His work includes managing R&D projects in the areas of oncology, respiratory, infectious disease, CNS therapeutics and medical devices as well as fundraising, licensing and M&A. He is the Co-Founder & Managing Director of Novateur Ventures, a premier global advisory group with over 100 senior life science advisors. Until recently he was Senior Vice President Device & Business Development for Beyond Air (NASDAQ:XAIR), where he was involved with the company from early stage until Nasdaq public offering and several rounds of financing and licensing. He is the CEO and co-founder of Optigo Biotherapeutics, an ophthalmology R&D company. He is the Vice Chair of LifeSciences BC, Entrepreneur in Residence at Innovation Boulevard and Calgary Innovation. He is an Associate at Creative Destruction Labs. He was the Co-Founder and COO of Niiki Pharma, which was acquired in 2013 by Intezyne Technologies, of which he became the Vice President. To date, he has taken several projects from concept to FDA approval (three 510ks) for medical devices in addition to several FDA IND approvals. He has also worked on commercialization and pharma partnerships and several global mergers and acquisitions.